CARLSBAD, Calif. / Oct 27, 2023 / Business Wire / Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the closing of its previously announced underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $10.50 per share.
Morgan Stanley, TD Cowen, Barclays and Stifel acted as joint book-running managers in the offering.
ATEC received gross proceeds from the offering of $150,150,000.
The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-271336) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). The offering was made by means of a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement, final prospectus supplement and accompanying prospectus relating to the offering were filed previously with the SEC and are available on the SEC’s website at www.sec.gov. The preliminary prospectus supplement, final prospectus supplement and accompanying base prospectus are available on the SEC’s website, and may also be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Cowen and Company, LLC, 599 Lexington Avenue, New York, New York 10022, by telephone at (833) 297-2926 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it.; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-888-603-5847 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it..
This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ATEC
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to be the Standard Bearer in Spine.
Last Trade: | US$9.19 |
Daily Change: | -0.14 -1.50 |
Daily Volume: | 712,051 |
Market Cap: | US$1.300B |
December 09, 2024 October 30, 2024 September 18, 2024 July 29, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB